Updated:
Enlivex
Enlivex is a clinical-stage immunotherapy company led by Oren Hershkovitz, developing Allocetra to treat sepsis by reprogramming macrophages.
Enlivex
Enlivex was founded in 2005 by CEO Oren Hershkovitz and is headquartered in Nes Ziona, Israel. The company operates as a clinical-stage immunotherapy developer listed on the Nasdaq, concentrating on macrophage reprogramming to resolve life-threatening inflammatory and oncological conditions. Enlivex's lead candidate, Allocetra, is designed to rebalance the immune system by targeting apoptotic cells. The company's development efforts have pivoted across several severe indications. Its most visible program targets sepsis-associated organ failure, a high-mortality condition with no approved immunotherapy. Prior clinical studies explored Allocetra in COVID-19-related acute respiratory distress syndrome and in graft-versus-host disease. The firm has conducted clinical trials at major medical centers in Israel and Europe. The company maintains a lean structure typical of an early-stage Israeli biotech, with research anchored in its Nes Ziona base. It has funded operations through public equity raises on the Nasdaq and previously the Tel Aviv Stock Exchange rather than through private asset-management vehicles. In February 2024, Enlivex reported that an independent data monitoring committee recommended continuation of its Phase II sepsis trial following a pre-planned interim safety and futility review (per the firm, February 2024). Unlike a single-family office deploying permanent capital or a venture firm running a diversified life-sciences portfolio, Enlivex operates as a publicly listed project-financed R&D entity. Its structural constraint and differentiator is a concentrated bet on one mechanism — macrophage reprogramming — with survival linked entirely to the clinical-readout trajectory of Allocetra.
General information
Firm type
Asset Manager
Year founded
2005
AUM
Undisclosed
Location
Region
Middle East
Country
Israel
City
Nes Ziona
Corporate office
Nes Ziona, Israel
Principals
Oren Hershkovitz
Chief Executive Officer
Sector focus
Frequently asked questions
What is Enlivex's lead drug candidate and how does it work?
Enlivex's lead candidate is Allocetra, an immunotherapy that aims to rebalance the immune system by reprogramming macrophages into a homeostatic state. The therapy involves infusing apoptotic cells that are engulfed by macrophages, shifting them from a pro-inflammatory to an anti-inflammatory, reparatory mode. This mechanism is being studied across severe inflammatory conditions, most notably sepsis-associated organ failure.
On which public exchange does Enlivex trade?
Enlivex is listed on the Nasdaq Capital Market under the ticker ENLV. The company's American Depositary Shares have traded there since completing its U.S. public offering. It was previously also listed on the Tel Aviv Stock Exchange before voluntarily delisting to consolidate trading in the U.S. market.
What is the current clinical development stage for Allocetra?
Allocetra is in an ongoing randomized, controlled Phase II clinical trial evaluating its efficacy in treating sepsis-associated organ failure. An independent data safety monitoring board reviewed unblinded safety and futility data in February 2024 and recommended the trial's continuation. Prior Phase II studies in COVID-19 ARDS and graft-versus-host disease were discontinued or deprioritized as the firm focused on the sepsis indication.
How does Enlivex fund its clinical operations?
As a clinical-stage company without significant product revenue, Enlivex funds its operations primarily through the issuance of equity on the Nasdaq. The firm has periodically raised capital via registered direct offerings, private placements, and at-the-market programs. Its cash management and burn rate are publicly disclosed each quarter in SEC filings.
Who leads the scientific and corporate strategy at Enlivex?
Oren Hershkovitz, Ph.D., serves as the Chief Executive Officer and was a co-founder of the company. The board includes prominent Israeli and American scientists. Notably, former Israeli Minister of Health Yael German and Prof. Shmuel Hess, an expert in hematology and immunotherapy, have served as directors, providing both clinical and regional regulatory guidance per the firm's public filings.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: